Benzinga | Nov 19, 2021 04:53AM EST

Piper Sandler Downgrades Vertex Pharmaceuticals to Neutral, Lowers Price Target to $218

Piper Sandler analyst Do Kim downgrades Vertex Pharmaceuticals (NASDAQ:VRTX) from Overweight to Neutral and lowers the price target from $323 to $218.